ID   Hs 695T
AC   CVCL_0851
SY   Hs 695.T; Hs-695-T; HS-695T; HS 695T; Hs695T; HS695T; Hs695
DR   CLO; CLO_0004053
DR   EFO; EFO_0006588
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ATCC; HTB-137
DR   BCRC; 60268
DR   BioGRID_ORCS_Cell_line; 652
DR   BioSample; SAMN03470910
DR   BioSample; SAMN10988229
DR   cancercelllines; CVCL_0851
DR   Cell_Model_Passport; SIDM01561
DR   ChEMBL-Cells; CHEMBL4523540
DR   ChEMBL-Targets; CHEMBL4523571
DR   CLS; 300211
DR   Cosmic; 933004
DR   DepMap; ACH-000799
DR   EGA; EGAS00001000610
DR   GEO; GSM206512
DR   GEO; GSM274686
DR   GEO; GSM887108
DR   GEO; GSM888179
DR   IARC_TP53; 30057
DR   LiGeA; CCLE_227
DR   PharmacoDB; Hs695T_586_2019
DR   Progenetix; CVCL_0851
DR   PubChem_Cell_line; CVCL_0851
DR   Wikidata; Q54895895
RX   PubMed=478563;
RX   PubMed=6500159;
RX   PubMed=6988327;
RX   PubMed=22282976;
RX   PubMed=22460905;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=26589293;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31978347;
CC   Part of: BRAF genetic alteration cell panel (ATCC TCP-1032).
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Population: Caucasian.
CC   Doubling time: ~48 hours (ATCC=HTB-137).
CC   HLA typing: A*02:01,02:01; B*49:01,49:01; C*07:01,07:01; DQA1*01:03,01:03; DQB1*06:03,06:03; DRB1*03:38,13:01 (PubMed=26589293).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (ATCC; DepMap).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0%; Native American=0.62%; East Asian, North=0.95%; East Asian, South=0.69%; South Asian=0.98%; European, North=71.17%; European, South=25.59% (PubMed=30894373).
CC   Misspelling: Hs 69ST; PubMed=25485619; PubMed=25877200.
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000027.
ST   Source(s): ATCC; CLS; PubMed=25877200
ST   Amelogenin: X,Y
ST   CSF1PO: 11
ST   D13S317: 12
ST   D16S539: 9,13
ST   D18S51: 18
ST   D21S11: 29
ST   D3S1358: 15
ST   D5S818: 9
ST   D7S820: 9,10
ST   D8S1179: 13,15
ST   FGA: 21,24
ST   Penta D: 9,12
ST   Penta E: 5,11
ST   TH01: 6
ST   TPOX: 8
ST   vWA: 18
DI   NCIt; C3802; Amelanotic melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_0850 ! Hs 695.Sk
SX   Male
AG   26Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 38
//
RX   PubMed=478563; DOI=10.1007/BF02616140;
RA   Creasey A.A., Smith H.S., Hackett A.J., Fukuyama K., Epstein W.L.,
RA   Madin S.H.;
RT   "Biological properties of human melanoma cells in culture.";
RL   In Vitro 15:342-350(1979).
//
RX   PubMed=6500159; DOI=10.1159/000163283;
RA   Gershwin M.E., Lentz D., Owens R.B.;
RT   "Relationship between karyotype of tissue culture lines and
RT   tumorigenicity in nude mice.";
RL   Exp. Cell Biol. 52:361-370(1984).
//
RX   PubMed=6988327; DOI=10.1007/BF02831503;
RA   O'Brien S.J., Shannon J.E., Gail M.H.;
RT   "A molecular approach to the identification and individualization of
RT   human and animal cells in culture: isozyme and allozyme genetic
RT   signatures.";
RL   In Vitro 16:119-135(1980).
//
RX   PubMed=22282976; DOI=10.1093/carcin/1.1.21;
RA   Day R.S. III, Ziolkowski C.H.J., Scudiero D.A., Meyer S.A.,
RA   Mattern M.R.;
RT   "Human tumor cell strains defective in the repair of alkylation
RT   damage.";
RL   Carcinogenesis 1:21-32(1980).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//